Janux CBO sells 16,665 shares after option exercises; Form 4 filed

Rhea-AI Filing Summary

Janux Therapeutics (JANX) Form 4: The company’s Chief Business Officer reported two option exercises and a subsequent sale on 10/28/2025. He exercised 9,999 options at $4.21 and 6,666 options at $10.59, then sold 16,665 shares.

The sale’s weighted average price was $30.0622, with trades between $30.00 and $30.49, executed under a Rule 10b5-1 trading plan adopted on September 30, 2024. Following these transactions, he directly beneficially owned 82,139 shares.

Insider Trade Summary

Net Seller: 16,665 shares ($500,987)

Net Sell 5 txns

Insider Meyer Andrew Hollman

Role Chief Business Officer

Sold 16,665 shs ($501K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	9,999	$0.00	--
Exercise	Stock Option (right to buy)	6,666	$0.00	--
Exercise	Common Stock	9,999	$4.21	$42K
Exercise	Common Stock	6,666	$10.59	$71K
Sale	Common Stock	16,665	$30.0622	$501K

Holdings After Transaction: Stock Option (right to buy) — 77,333 shares (Direct); Common Stock — 92,138 shares (Direct)

Footnotes (1)

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024. The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Immediately exercisable.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyer Andrew Hollman

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/28/2025		M		9,999	A	$4.21	92,138	D
Common Stock	10/28/2025		M		6,666	A	$10.59	98,804	D
Common Stock	10/28/2025		S(1)		16,665	D	$30.0622(2)	82,139	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.21	10/28/2025		M			9,999	(3)	03/09/2031	Common Stock	9,999	$0	77,333	D
Stock Option (right to buy)	$10.59	10/28/2025		M			6,666	(3)	05/13/2031	Common Stock	6,666	$0	121,434	D

Explanation of Responses:

1. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

2. The weighted average sale price for the transaction reported was $30.0622 and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. Immediately exercisable.

	/s/ James Pennington, Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.